Floatz logo

Clostridium Butyricum

Colon Neoplasm

Second Affiliated Hospital, School of Medicine, Zhejiang Universityother_biologicalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Colon Neoplasm cohort.

Asset / SponsorPhaseRating
Tranexamic Acid
Assaf-Harofeh Medical Center
Phase 4BB
Eloxatin
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2BB
FLUOROURACILUM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2BB
Cetuximab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B
Regorafenib
City of Hope Medical Center
Phase 2B

View all 34 →

Same molecule, other indications

Clostridium Butyricum is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
62 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →
Low Anterior Resection SyndromeDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →